Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KNC Laboratories CoFRA:7LW -2.02%81 EBITDA Margin % is 31.93% as of Mar. 2026, which is 11% above its 10-year median of 28.78. GuruFocus rates FRA:7LW with a GF Score™ of 81/100 and a GF Value™ of €6.31. The stock has 9 warning signs investors should review. Among 1,578 Chemicals companies, KNC Laboratories Co ranks better than 90.75% on this metric.
KNC Laboratories Co (FRA:7LW) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
KNC Laboratories Co EBITDA Margin % Related Terms
KNC Laboratories Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for KNC Laboratories Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, KNC Laboratories Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KNC Laboratories Co EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, KNC Laboratories Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where KNC Laboratories Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNC Laboratories Co (FRA:7LW) has a EBITDA Margin % of 31.93% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KNC Laboratories Co and its competitors. This is 11% above median its historical median of 28.78. Over the past decade, KNC Laboratories Co's EBITDA Margin % has ranged from 22.33 to 35.94. According to the industry distribution chart, KNC Laboratories Co ranks #146 out of 1578 companies in the Chemicals industry, placing it in the top 9.3%.
Is KNC Laboratories Co's EBITDA Margin % too high?
KNC Laboratories Co's current EBITDA Margin % of 31.93% is 11% above median its 10-year median of 28.78. Over the past 10 years, this metric has ranged from a low of 22.33 to a high of 35.94. The Chemicals industry median EBITDA Margin % is 9.63. KNC Laboratories Co's value of 31.93% is 231.7% above this industry median. Based on the distribution chart, KNC Laboratories Co ranks #146 out of 1578 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, KNC Laboratories Co has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does KNC Laboratories Co's EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, KNC Laboratories Co ranks #146 out of 1578 companies for EBITDA Margin %. This places KNC Laboratories Co in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.63. KNC Laboratories Co's value of 31.93% is 231.7% above this benchmark. Historically, KNC Laboratories Co's own EBITDA Margin % has ranged from 22.33 to 35.94 over the past decade. While the company's 10-year median is 28.78 vs. the industry median of 9.63, KNC Laboratories Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,578 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KNC Laboratories Co's current EBITDA Margin % of 31.93% is 231.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KNC Laboratories Co and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KNC Laboratories Co's current EBITDA Margin % is 31.93%, which is 11% above median its own 10-year median of 28.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KNC Laboratories Co stock overvalued right now?
KNC Laboratories Co (FRA:7LW) has a current EBITDA Margin % of 31.93%. The stock's GF Value™ is €6.31, compared to a current price of €6.30 — trading 0.2% below its estimated fair value. The current EBITDA Margin % is 31.93%, which is 11% above median its 10-year median of 28.78 and 231.7% above the Chemicals industry median of 9.63. KNC Laboratories Co's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For KNC Laboratories Co (FRA:7LW), the current EBITDA Margin % is 31.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KNC Laboratories Co (FRA:7LW) Overvalued in 2026?
Based on GuruFocus' analysis, KNC Laboratories Co stock appears to be undervalued.
The current stock price of €6.30 is trading 0.2% below its estimated GF Value™ of €6.31.
Key valuation signals for FRA:7LW:
EBITDA Margin %: 31.93% (11% above median its 10-year median of 28.78)
GF Value™: €6.31 vs. price of €6.30 (0.2% below fair value)
Industry Position: 231.7% above the Chemicals median (#146 of 1578)
No single metric tells the full story. See the FRA:7LW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7LW has been successfully added to your 
